GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer Read more about GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology Read more about Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019 Read more about Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Read more about Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress Read more about MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
Asian Sub-Group Analysis of Novocure’s EF-14 Phase 3 Trial of Optune® in Newly Diagnosed Glioblastoma Presented at ASNO 2019 Demonstrating Efficacy and Safety Benefits Read more about Asian Sub-Group Analysis of Novocure’s EF-14 Phase 3 Trial of Optune® in Newly Diagnosed Glioblastoma Presented at ASNO 2019 Demonstrating Efficacy and Safety Benefits
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer Read more about Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting Read more about Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress Read more about Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for Medical Oncology (ESMO) 2019 Congress
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections Read more about The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections